塔苏斯制药（Tarsus Pharmaceuticals，股票代码：TARS）今日盘前大涨7.44%，引发市场广泛关注。这一显著涨幅主要源于公司最新公布的第二季度财报超出市场预期。
根据财报显示，塔苏斯制药第二季度营收同比大幅增长151.5%，达到1.0266亿美元，远超分析师预期的9568万美元。尽管公司报告每股亏损48美分，略高于分析师预期的40美分亏损，但相比去年同期88美分的亏损已有明显改善。值得注意的是，公司本季度净亏损为2034万美元，显示出公司财务状况正在逐步改善。
尽管季度业绩仍处于亏损状态，但华尔街分析师对塔苏斯制药的前景保持乐观。目前，分析师对该公司股票的平均评级为"强力买入"，其中7个评级为"强力买入"或"买入"，1个为"持有"，没有"卖出"或"强力卖出"评级。分析师给出的12个月目标价中位数为72.00美元，较上一交易日收盘价41.15美元高出约42.8%。这些积极的分析师评级和远高于当前价格的目标价可能是推动股价大涨的另一个重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.